Tag Archives: The State of Patent Eligibility

XY, LLC v. Trans Ova Genetics, Inc. – Building on Illumina v. Ariosa

In XY v. Trans Ova Genetics, Inc., Appeal No. 2019-1789 (Fed. Cir. July 31, 2020), a panel of Wallach, Plager and Stoll reversed the district court’s finding that claims to an improved method of cell sorting are patent ineligible under … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , | Leave a comment

AAM v. Neapco – Part IV – Petition for Rehearing En Banc Denied – “Bad Vibrations”

This post will briefly discuss the Fed. Cir.’s denial of rehearing en banc – which  left the modified panel opinion stand. The lengthy panel opinion has been the subject of my last three posts, and you should read them before … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , | Leave a comment

CardioNet v. Infobionics: The Requirement for Improvements in Patent Eligibility

This decision, Appeal No. 2019-1149 (Fed. Cir. April 17th 2020) should have required about 13 pages and could have ended after the first paragraph under Section A. Instead, a split panel required a 23 page majority decision and a 10 … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , , | Leave a comment

Solicitor General’s Briefs Encourage Supreme Court to Put s. 101 Back on Track

Earlier this year, the Supreme Court issued orders to the Solicitor General to weigh in on whether or not the Court should grant cert. in two high profile Fed. Cir. decisions: Hikma Pharm. USA Inc, v. Vanda Pharm. Inc., No. … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , | Leave a comment